Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE) have been deemed as serious threats by the CDC. Many chronic MRSA and VRE infections are due to biofilm formation. Biofilm are considered to be between 10–10,000 times more resistant to antibiotics, and therefore new chemical entities that inhibit and/or eradicate biofilm formation are needed. Teichoic acids, such as lipoteichoic acids (LTAs) and wall teichoic acids (WTAs), play pivotal roles in Gram-positive bacteria’s ability to grow, replicate, and form biofilms, making the inhibition of these teichoic acids a promising approach to fight infections by biofilm forming bacteria. Here, we describe the potent biofilm inhibition activity against MRSA and VRE biofilms by two LTA biosynthesis inhibitors HSGN-94 and HSGN-189 with MBICs as low as 0.0625 µg/mL against MRSA biofilms and 0.5 µg/mL against VRE biofilms. Additionally, both HSGN-94 and HSGN-189 were shown to potently synergize with the WTA inhibitor Tunicamycin in inhibiting MRSA and VRE biofilm formation.
Highlights
Antimicrobial-resistant bacteria have become a serious global health issue
We previously identified HSGN-94 and HSGN-189 as novel lipoteichoic acids (LTAs) biosynthesis inhibitors
We demonstrate that these compounds have potent inhibition of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE) biofilms with Minimum Biofilm Inhibition Concentration (MBIC) well below compounds’ MICs
Summary
Antimicrobial-resistant bacteria have become a serious global health issue. Organization (WHO) acknowledges that every year 700,000 people die from drug-resistant infections worldwide. It has been estimated that deaths from drug-resistant infections will reach 10 million people per year by 2050, surpassing deaths due to cancer [1]. The Centers for Disease Control and Prevention (CDC, USA) has reported that on average two million people are inflicted with an antibiotic-resistant infection every year, and at least 23,000 people die from these infections [2]. Of these drug-resistant bacteria, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.